Table 3.

TP53 status in CLL patients with p53 dysfunction

CaseBase changePredicted codon change
63-150 None None 
83-150 None None  
93-151 413 C→T (exon 5) 138 A→V  
103-151 430 C→T (exon 5) 144 Q→stop  
113-151 584 T→A (exon 6) 195 I→N 
123-151 764 T→A (exon 7) 255 I→N 
193-150 None None  
243-150 None None 
353-150 None None  
363-150 None None 
393-151 743 G→A (exon 7) 248 R→Q 
403-150 None None  
423-151 673-681 del 9nt del 225-227 V,G,S 
CaseBase changePredicted codon change
63-150 None None 
83-150 None None  
93-151 413 C→T (exon 5) 138 A→V  
103-151 430 C→T (exon 5) 144 Q→stop  
113-151 584 T→A (exon 6) 195 I→N 
123-151 764 T→A (exon 7) 255 I→N 
193-150 None None  
243-150 None None 
353-150 None None  
363-150 None None 
393-151 743 G→A (exon 7) 248 R→Q 
403-150 None None  
423-151 673-681 del 9nt del 225-227 V,G,S 

All 13 patients with type B

F3-150

or A

F3-151

p53 dysfunction were subjected to TP53 mutation analysis. The entire coding region was sequenced in both orientations from a combination of genomic PCR and RT-PCR products, as detailed in “Patients, materials, and methods.” Nucleotide positions relate to cDNA and are numbered from the ATG codon.

or Create an Account

Close Modal
Close Modal